Breaking News, Collaborations & Alliances

Matica Bio, Mongoose Bio Partner to Accelerate TCR-T Cell Therapy Development

Will focus on the development and production of lentivirus for Mongoose Bio's TCR-T pipeline for cancer treatment.

Author Image

By: Charlie Sternberg

Associate Editor

Matica Biotechnology, a Texas-based viral vector Contract Development and Manufacturing Organization (CDMO), has entered a strategic partnership with Mongoose Bio focused on the full development and production of lentivirus for Mongoose Bio’s T cell receptor-engineered T cell (TCR-T) pipeline for cancer treatment.   Under the terms of the agreement, Matica Bio will provide comprehensive services, including process development, analytical method development, and the manufacturing of non-c...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters